We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is “making the process for copying these medicines more efficient and creating an easier path for generic alternatives to enter the market,” said Commissioner Scott Gottlieb. Read More
The European Commission based its approval on a Phase 3 clinical trial showing vision improvement as early as 30 days following treatment. Vision improved for 90 percent of trial subjects. Read More